Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723810 · ClinicalTrials.gov registry record · Phase 1
TumorGlow Intraoperative Molecular Imaging (IMI)
A Phase 1 study of Tumor, Solid, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT04723810: Recruiting Phase 1 study of Tumor, Solid, sponsored by University of Pennsylvania.
NCT04723810 is a Phase 1 study of Tumor, Solid that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 500 participants, above the 198-participant average among 11 other Tumor, Solid trials with a reported enrollment target (153% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04723810, a Phase 1 study of Tumor, Solid, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.
Primary Outcome
Type, frequency, severity, and attribution of AEs/SAEs (all tumor types combined).
Conditions Studied
Interventions
- DRUG Indocyanine Green
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2027-01-14 |
| Phase | Phase 1 |
What NCT04723810 shows while recruiting
NCT04723810 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 198-participant average among 11 other Tumor, Solid trials with a reported enrollment target (153% higher).
The record links to 1 condition, with Tumor, Solid appearing as the primary indexed condition, and to 1 intervention - of which Indocyanine Green is the first listed.
NCT04723810 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04723810 about?
NCT04723810 is a clinical study titled "TumorGlow Intraoperative Molecular Imaging (IMI)". This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided ...
What is the current status of trial NCT04723810?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 500 participants. The study started on 2024-08-14. Estimated completion is 2027-01-14.
What conditions does trial NCT04723810 study?
This clinical trial studies the following conditions: Tumor, Solid.
What interventions are being tested in trial NCT04723810?
The interventions under investigation include: Indocyanine Green (DRUG).
Who is sponsoring clinical trial NCT04723810?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04723810 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor, Solid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04723810's enrollment target sits among peer trials
500 2nd of 11 the highest of 11 other Tumor, Solid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumor, Solid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
RECRUITING · Phase 1
-
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
RECRUITING · Phase 1
-
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI